樹状細胞と肝疾患の免疫病態および治療

Onji, Morikazu

doi:10.2177/jsci.27.64

Jpn. J. Clin. Immunol.

2004

DOI: 10.2177/jsci.27.64

|View full text |Cite

樹状細胞と肝疾患の免疫病態および治療

Morikazu Onji

Abstract: \ 1 ÷ó×EÌÁ¥ 1) AEuÄ@\ ªzíGSgCR´ß¨Ìã®pí¯ÉÚ® 2) R´ñ¦\ R´Ìß¨CCñ¦ðs¤ áxÌR´Åà¢AEuðU±•é 3)`ÔG¬nÈ¢µÍ«»•éAE½Ì÷}óËNðÂ 4) ½^«FíÞC¬nßöCªzíÉaeè«óªÙÈé 5) AEuÌJn_Åìp ¢´ì TC[ T, B, NK, NKT ×Eðh 6) AEu°eðU± «C½«AEu°eðU± 7) «»³ê½ NK ×EÉaeè¢nÈ÷ó×EÍ³êé 8) ©RAEuÉÖ1^C ^[tFY ¶÷ó×EÌ ¶Ý

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Production of functional dendritic cells from menstrual blood—a new dendritic cell source for immune therapy

Pham

Lam

et al. 2011

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

Dendritic cells (DCs) are the most professional antigen-presenting cells of the mammalian immune system. They are able to phagocytize, process antigen materials, and then present them to the surface of other cells including T lymphocytes in the immune system. These capabilities make DC therapy become a novel and promising immune-therapeutic approach for cancer treatment as well as for cancer vaccination. Many trials of DC therapy to treat cancers have been performed and have shown their application value. They involve harvesting monocytes or hematopoietic stem cells from a patient and processing them in the laboratory to produce DCs and then reintroduced into a patient in order to activate the immune system. DCs were successfully produced from peripheral, umbilical cord blood-derived monocytes or hematopoietic stem cells. In this research, we produced DCs from human menstrual blood-derived monocytes. Briefly, monocytes were isolated by FACS based on FSC vs. SSC plot from lysed menstrual blood. Obtained monocytes were induced into DCs by a two-step protocol. In the first step, monocytes were incubated in RPMI medium supplemented with 2% FBS, GM-CSF, and IL-4, followed by incubation in RPMI medium supplemented with α-TNF in the second step. Our data showed that induced monocytes had typical morphology of DCs, expressed HLA-DR, HLA-ABC, CD80 and CD86 markers, exhibited uptake of dextran-FITC, stimulated allogenic T cell proliferation, and released IL-12. These results demonstrated that menstrual blood can not only be a source of stromal stem cell but also DCs, which are a potential candidate for immune therapy.

show abstract

Production of functional dendritic cells from menstrual blood—a new dendritic cell source for immune therapy

Pham

Lam

et al. 2011

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

樹状細胞と肝疾患の免疫病態および治療

Cited by 1 publication

References 56 publications

Production of functional dendritic cells from menstrual blood—a new dendritic cell source for immune therapy

Production of functional dendritic cells from menstrual blood—a new dendritic cell source for immune therapy

Contact Info

Product

Resources

About